L’Oréal Charged Parents 30 Percent More for Identical Skincare Products Relabeled with Toy Blocks

THE MANUFACTURED DISTINCTION

On June 2024, Monica Raymundo purchased a tube of CeraVe Baby Healing Ointment from Amazon. She paid a premium because the product was marketed as specially formulated for infants. The labeling featured the word “Baby” styled as toy blocks. The packaging stated it was “Developed with Pediatric Dermatologists.” The website categorized it under “For Baby Skin.” The message was unambiguous: this product was designed for babies in a way the standard version was not.

The message was a lie.

According to the class action complaint filed July 9, 2026 in the United States District Court for the Southern District of California (Case No. 3:26-cv-03951-RBM-DEB), the CeraVe Baby Healing Ointment Raymundo purchased contains the exact same active ingredient at the exact same concentration as the standard CeraVe Healing Ointment. It contains the exact same inactive ingredients listed in the exact same order. The directions for use are identical: “apply as needed.” The only material difference is the label and the price.

The “Baby” designation falsely conveys that the Baby Products possess characteristics or qualities that distinguish them from the Standard Products when, in fact, no such material distinctions exist.

L’Oréal USA S/D, Inc., the defendant named in the lawsuit, is a Delaware corporation headquartered in New York. It manufactures, markets, distributes, and sells the CeraVe product line. The complaint alleges L’Oréal engaged in a deliberate scheme to extract price premiums from parents and caregivers by creating the false impression that the Baby Products were formulated differently from, and were more appropriate for infants than, the standard versions of the same products.

The scheme worked because it exploited parental fear. Parents exercise heightened caution when selecting skincare products for infants. They are primed to trust labels that signal safety and specialized formulation. L’Oréal knew this. The company created a separate product line, applied baby-specific branding and pediatric-dermatologist endorsements, and charged a premium. It did so without altering the formulation in any material way.

This is at the core a story about systemic extraction of wealth from families through manufactured product differentiation.

THE INGREDIENT INVENTORY

The complaint provides exhaustive side-by-side ingredient comparisons for both product pairs: the Healing Ointments and the Eczema Creams. These comparisons form the evidentiary backbone of the fraud allegation.

CeraVe Baby Healing Ointment vs. CeraVe Healing Ointment

Active Ingredient (Both Products): Petrolatum 46.5%

Inactive Ingredients (Both Products, Same Order): Mineral oil, paraffin, ozokerite, dimethicone, ceramide NP, ceramide AP, ceramide EOP, carbomer, water, sodium lauroyl lactylate, proline, cholesterol, phenoxyethanol, tocopheryl acetate, tocopherol, hydrolyzed hyaluronic acid, panthenol, pantolactone, phytosphingosine, xanthan gum, ethylhexylglycerin.

Directions for Use (Both Products): Apply as needed.

CeraVe Baby Eczema Cream vs. CeraVe Eczema Moisturizing Cream

Active Ingredient (Both Products): Colloidal oatmeal 1%

Inactive Ingredients (Both Products, Same Order): Water, butyrospermum parkii (shea) butter, glycerin, dimethicone, cetearyl alcohol, niacinamide, caprylic/capric triglyceride, glyceryl stearate, PEG-100 stearate, ammonium polyacryloyldimethyl taurate, ceramide NP, ceramide AP, ceramide EOP, sorbitan tristearate, carbomer, cetearyl isononanoate, behentrimonium methosulfate, triethyl citrate, sodium benzoate, sodium lauroyl lactylate, sodium hyaluronate, cholesterol, phenoxyethanol, tocopherol, citric acid, caprylyl glycol, trisodium ethylenediamine disuccinate, xanthan gum, pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate, phytosphingosine, octyldodecanol, benzoic acid, PEG-20 methyl glucose sesquistearate.

Directions for Use (Both Products): Apply as needed.

The identical active ingredient concentrations indicate identical therapeutic function. The identical inactive ingredient lists, presented in the same order, strongly suggest identical formulation processes and material composition. The identical directions for use confirm there is no specialized application protocol for infant skin that would justify the Baby designation.

The complaint states: “The identical active-ingredient strength, together with the matching inactive ingredients listed in the same order, strongly indicates that each Baby Product and its corresponding Standard Product are formulated identically, and are materially indistinguishable for purposes of use by consumers of any age or life stage.”

L’Oréal possesses the formulation records, manufacturing protocols, and internal testing data that would definitively prove or disprove this allegation. The company has not made that data public. The complaint alleges L’Oréal “knew or, in the exercise of reasonable care, should have known that these representations were untrue or misleading, because L’Oréal formulates, labels, and markets both the Baby Products and the Standard Products and knows they are materially identical.”

THE PRICE EXTRACTION MECHANISM

The financial dimension of the alleged fraud is documented with precision. The complaint includes pricing data from multiple national and online retailers, calculated on both a per-unit and per-ounce basis.

CeraVe Baby Eczema Cream (5 oz) vs. CeraVe Eczema Moisturizing Cream (8 fl oz)

The Baby Eczema Cream is sold in a smaller container (5 oz vs. 8 fl oz), which obscures the per-ounce price differential at the point of sale. Consumers comparing the products see a lower absolute price for the Baby version and may assume it represents better value for a product marketed as specially formulated. The per-ounce analysis reveals the opposite: parents pay between 19 percent (cerave.com) and 30 percent (Amazon) more per ounce for the Baby-labeled product.

CeraVe Baby Healing Ointment (3 oz) vs. CeraVe Healing Ointment (3 oz)

The Healing Ointment comparison is even more stark because both products are sold in identical 3 oz containers. There is no size differential to obscure the price gap. Parents at CVS paid $14.49 for the Baby version and $10.79 for the standard version of the same product. That is a $3.70 markup, a 34 percent premium, for toy-block lettering and a “For Baby Skin” categorization on the website.

The complaint argues: “Because each Baby Product is materially identical to its corresponding Standard Product, this premium reflects the economic value of the misleading representation, rather than any difference in the products.”

The price premium is not incidental. It is the purpose. L’Oréal created a product differentiation where none existed in order to segment the market and extract higher margins from a consumer base primed to pay more for perceived safety and specialization.

THE MARKETING APPARATUS

The deception extended beyond the physical packaging. L’Oréal reinforced the false product distinction through deliberate website categorization, targeted marketing copy, and the strategic use of pediatric-dermatologist endorsements.

On L’Oréal’s CeraVe website, the Baby Healing Ointment was grouped under a category labeled “For Baby Skin.” The standard Healing Ointment was grouped separately under “For Dry to Very Dry Skin.” This categorical separation created the impression of distinct product lines designed for distinct user populations. A parent navigating the site would reasonably conclude the Baby product was formulated for infants and the standard product was formulated for adults.

The product page for the Baby Eczema Cream stated the product was “Developed with pediatric dermatologists” and featured copy emphasizing that its “gentle, fragrance-free formula is designed specifically for baby eczema” and helps maintain “babies’ 30% thinner skin barrier.” The corresponding standard Eczema Cream was marketed merely as “Developed with dermatologists,” with no mention of pediatric specialization or infant-specific formulation.

These representations are not passive descriptions. They are active inducements. The complaint alleges: “Through the ‘Baby’ designation, the pediatric-dermatologist references, and related ‘baby’ imagery, including the use of toy blocks to spell out ‘BABY,’ L’Oréal represents to reasonable consumers that the Baby Products are specially formulated—that their composition itself is tailored to the distinct physiology of infant skin—and are therefore materially different from, and more appropriate for infants than, the corresponding Standard Products.”

L’Oréal’s own promotional materials confirm the labeling change was cosmetic, not chemical. The complaint cites internal L’Oréal messaging stating that when the company updated the Baby Healing Ointment packaging to add the toy-block “Baby” styling, it represented the change as a “new look” but the “same great formula.” The company acknowledged the packaging was new. The formula was not.

The “Baby” designation thus reflects a marketing choice, not a formulation difference, and consumers have no reasonable way to discover from the disparate labeling that the products are materially identical.

The deliberate omission is as important as the affirmative misrepresentation. L’Oréal separated the product lines, emphasized infant-specific development for the Baby versions, and failed to disclose that the standard versions shared the same ingredients, characteristics, and uses. A consumer comparing the Baby Healing Ointment to the standard Healing Ointment at the point of sale would have no reason to suspect they were purchasing the same formulation at different price points.

THE NON-FINANCIAL LEDGER

The economic harm is quantifiable. The dignity harm is not. Parents who purchased the Baby Products did so because they wanted to provide the safest, most appropriate care for their infants. They read the labels. They paid attention to the pediatric-dermatologist endorsements. They made the rational choice to spend more money on a product marketed as specially formulated for their child’s sensitive skin.

They were deceived.

The deception is compounded by the fact that many of these same parents likely already owned, or could have used, the standard versions of the same products. A parent who purchased both the Baby Healing Ointment and the standard Healing Ointment for different family members paid for the same formulation twice. The distinction was a fiction. The expenditure was real.

The complaint centers Monica Raymundo as the named plaintiff. Raymundo is a California citizen residing in San Diego County. She purchased the Baby Healing Ointment in June 2024 from Amazon for her own personal and household use. She relied on the Baby labeling and related representations. She understood those representations to mean the product was specially formulated and uniquely appropriate for use on infants. She acted reasonably. She was willing to pay a premium based on that belief. She paid it.

The harm extends to the class. The complaint seeks to represent all persons in California who, at any time from four years prior to the filing date through the date a class is notified, purchased CeraVe Baby Healing Ointment or CeraVe Baby Eczema Cream for personal or household use, and not for resale or distribution. The class size is not specified, but the products are sold at major national retailers including Target, Walmart, CVS, and Amazon, as well as through L’Oréal’s own website. The number of affected consumers is likely in the tens of thousands at minimum.

The complaint alleges: “Parents and caregivers of infants and young children exercise heightened caution when selecting skincare products for their children and reasonably place particular weight on representations indicating a product is specifically formulated for babies. As a result, they are especially likely to rely on ‘Baby’ labeling in deciding which product to purchase.”

This is not generalized consumer annoyance. This is targeted exploitation of a population segment that is structurally vulnerable to this exact form of deception. New parents are navigating an overwhelming volume of product choices in a high-stakes environment where the consequences of a wrong choice feel catastrophic. Companies know this. They design marketing strategies around it. L’Oréal is accused of doing exactly that.

LEGAL RECEIPTS

“L’Oréal’s acts, omissions, misrepresentations, and practices alleged herein constitute business acts and practices. A business act or practice is ‘fraudulent’ under the UCL if it is likely to deceive a significant portion of the public, applying an objective reasonable-consumer test. As alleged herein, L’Oréal’s ‘Baby’ representations and related representations and omissions are likely to deceive reasonable consumers into believing that the Baby Products are specially formulated and uniquely appropriate for use on infants, and therefore materially different from—and a more suitable choice for infants than—the Standard Products.”
— Raymundo v. L’Oréal USA S/D, Inc., Case 3:26-cv-03951-RBM-DEB, ¶53

“The identical active-ingredient strength, together with the matching inactive ingredients listed in the same order, strongly indicates that each Baby Product and its corresponding Standard Product are formulated identically, and are materially indistinguishable for purposes of use by consumers of any age or life stage.”
— Raymundo v. L’Oréal USA S/D, Inc., Case 3:26-cv-03951-RBM-DEB, ¶18

“L’Oréal knew or, in the exercise of reasonable care, should have known that these representations were untrue or misleading, because L’Oréal formulates, labels, and markets both the Baby Products and the Standard Products and knows they are materially identical.”
— Raymundo v. L’Oréal USA S/D, Inc., Case 3:26-cv-03951-RBM-DEB, ¶62

“Reasonable consumers would not have paid a premium for the Baby Products had they known they were materially identical to L’Oréal’s less expensive Standard Products.”
— Raymundo v. L’Oréal USA S/D, Inc., Case 3:26-cv-03951-RBM-DEB, ¶32

“The premium therefore reflects the value consumers place on the false ‘Baby’ distinction, and demonstrates that the distinction is material to purchasing decisions.”
— Raymundo v. L’Oréal USA S/D, Inc., Case 3:26-cv-03951-RBM-DEB, ¶34

SOCIETAL IMPACT MAPPING

Economic Inequality: The Parental Tax

The Baby Product price premium functions as a regressive tax on families with infants. The economic burden falls disproportionately on lower-income households, who are more likely to perceive baby-specific products as necessary rather than optional and who have fewer resources to absorb the markup.

The pricing structure creates a two-tier system: families who can afford to pay the premium for the perceived safety of Baby-labeled products, and families who cannot. The latter group may experience anxiety and guilt over purchasing the “wrong” product, despite the fact that the standard and Baby versions are materially identical. The inequality is not just financial. It is psychological. L’Oréal profits from both.

The aggregate wealth extraction is substantial. If the average Baby Product purchaser pays a $3.00 premium per unit, and if the products are purchased by even a conservative estimate of 100,000 California consumers during the class period, the total extraction exceeds $300,000 from California residents alone. The national figure would be multiples higher.

That capital does not circulate in the communities that generated it. It flows upward to L’Oréal’s shareholders and executive compensation packages. The company’s parent entity, L’Oréal S.A., is a publicly traded French multinational corporation with annual revenues exceeding $40 billion. The Baby Product premiums represent rounding errors in the corporate ledger. They represent material budget impacts for the families who paid them.

Public Health: The Erosion of Trust

The alleged deception extends beyond individual transactions. It degrades trust in the product labeling system that consumers rely on to make informed health and safety decisions. When a major corporation markets a product line as specially formulated for infants, consumers reasonably assume that representation is subject to regulatory oversight and factual accuracy. If the representation is false, and if the deception is systemic and profitable, the signal-to-noise ratio in the consumer marketplace deteriorates.

Parents scanning product labels in a pharmacy aisle operate under severe information asymmetry. They do not have access to formulation data, clinical testing results, or internal corporate communications. They rely on the labels as shorthand for safety and appropriateness. When labels become marketing vehicles disconnected from material product characteristics, the labeling system fails its informational function.

The complaint alleges L’Oréal “had a duty to exercise reasonable care in supplying accurate information to consumers concerning the characteristics, qualities, and intended use of the Baby Products because it knew consumers would rely on that information in deciding whether to purchase the products.” If that duty was breached, the breach is not an isolated incident. It is a systemic feature of a business model that prioritizes margin optimization over informational honesty.

Environmental Degradation: The Redundancy Waste Stream

The creation of duplicate product lines generates waste. Families who purchase both Baby and standard versions of the same formulation consume twice the packaging, twice the shipping resources, and twice the retail shelf space for identical chemical contents. The redundancy is environmental waste produced by marketing strategy.

The smaller container sizes used for Baby Products may appear resource-efficient, but the per-ounce cost analysis suggests otherwise. Consumers purchasing the 5 oz Baby Eczema Cream instead of the 8 oz standard version consume more packaging material per unit of product. The environmental cost of that inefficiency is externalized to the commons. The profit from the price premium is internalized to L’Oréal.

THE COST OF A LIFE METRIC

WHAT NOW?

The complaint was filed July 9, 2026 by Fitzgerald Monroe Flynn PC on behalf of Monica Raymundo. The case is assigned to the United States District Court for the Southern District of California under Case No. 3:26-cv-03951-RBM-DEB. The lawsuit seeks class certification, injunctive relief, restitution, corrective advertising, punitive damages, and attorneys’ fees.

The named plaintiff seeks to represent all California residents who purchased CeraVe Baby Healing Ointment or CeraVe Baby Eczema Cream for personal or household use during the four-year period prior to filing. The class definition excludes purchases for resale or distribution.

The legal claims include violations of California’s Unfair Competition Law (Cal. Bus. & Prof. Code §§ 17200 et seq.), violations of California’s False Advertising Law (Cal. Bus. & Prof. Code §§ 17500 et seq.), violations of California’s Consumers Legal Remedies Act (Cal. Civ. Code §§ 1750 et seq.), negligent misrepresentation, and unjust enrichment.

The plaintiff complied with the pre-filing notice requirement under the Consumers Legal Remedies Act, notifying L’Oréal in writing by certified mail more than 30 days before filing, and demanding corrective action. L’Oréal did not comply.

What You Can Do:

• Document Your Purchases: If you purchased CeraVe Baby products in California, retain receipts, order confirmations, and product packaging. This documentation may be relevant to class membership.
• Report to Regulatory Bodies: File complaints with the Federal Trade Commission (FTC) Consumer Sentinel Network and the California Attorney General’s Office Consumer Protection Section if you believe you were deceived by Baby Product labeling.
• Support Ingredient Transparency Advocacy: Organizations like the Environmental Working Group (EWG) and the Campaign for Safe Cosmetics maintain databases and advocacy efforts around cosmetic product labeling accuracy.
• Pressure Retailers: Contact the corporate offices of retailers that carry CeraVe Baby Products and demand they verify L’Oréal’s product differentiation claims before continuing to stock products with disputed labeling.
• Spread the Ingredient Lists: Share the side-by-side ingredient comparisons from this article with parent networks, childcare cooperatives, and mutual aid groups. Information asymmetry is the weapon. Dissemination is the counter-strategy.

Watchlist:

Federal Trade Commission (FTC) — Bureau of Consumer Protection
California Attorney General’s Office — Consumer Protection Section
U.S. Food and Drug Administration (FDA) — Office of Cosmetics and Colors
Better Business Bureau — Advertising Review Programs

The courtroom is one arena. The pharmacy aisle is another. Parents armed with ingredient lists and pricing data can make purchasing decisions that do not subsidize corporate deception. Collective refusal to pay the Baby Tax is a form of economic resistance. The formula is disclosed. The choice is yours.